Clinical Trials · NCT03002428
A Comparison of PF708 and Forteo in Osteoporosis Patients
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Pfenex, Inc
- Enrollment
- 181
- Start date
- Dec 2016
- Locations
- 26 sites, United States
- Primary endpoint
- Blood levels of anti-drug antibody (ADA) against teriparatide